Ketamine for resistant depression: a scoping review.

Autor:	Eduardo TQ; Medicine School, Universidad de La Sabana, Chía, Colombia., Angela A; Medicine School, Universidad de La Sabana, Chía, Colombia., Mateo L; Medicine School, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia., Melanie LZ; Medicine School, Universidad del Norte, Barranquilla, Colombia., Valentina PF; Medicine School, Universidad del Norte, Barranquilla, Colombia., David C; Medicine School, Universidad de La Sabana, Chía, Colombia., Estefania C; Medicine School, Universidad de La Sabana, Chía, Colombia., Natalia RS; Medicine School, Fundación Universitaria Juan N Corpas, Bogotá, Colombia., Andrés VC; Internal Medicine Program, Universidad de Autónoma de Bucaramanga,Colombia., Angel RO; Medicine School, Universidad del Rosario, Bogotá, Colombia., Juan G; Medicine School, Universidad de La Sabana, Chía, Colombia., Juan P; Medicine School, Universidad de La Sabana, Chía, Colombia.
Jazyk:	angličtina
Zdroj:	Actas espanolas de psiquiatria [Actas Esp Psiquiatr] 2022 May; Vol. 50 (3), pp. 144-159. Date of Electronic Publication: 2022 May 01.
Abstrakt:	Ketamine is a fast-acting anesthetic with hypnotic properties. Moreover, could potentially improve affective symptoms in patients with refractory depressive disorder. Objective. explore the scientific literature available until December 10, 2021, about the efficacy and safety of ketamine in patients with treatment-refractory major depressive disorder. Material and methods. Scoping review that included PubMed and Scopus. Records of clinical trials and publications with empirical data in English and Spanish were included.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu